Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer

Open access
Zhao, Na, Cao, Jin, Xu, Longyong, Tang, Qianzi, Dobrolecki, Lacey E., Lv, Xiangdong, Talukdar, Manisha, Lu, Yang, Wang, Xiaoran, Hu, Dorothy Z., Shi, Qing, Xiang, Yu, Wang, Yunfei, Liu, Xia, Bu, Wen, Jiang, Yi, Li, Mingzhou, Gong, Yingyun, Sun, Zheng, Ying, Haoqiang, Yuan, Bo, Lin, Xia, Feng, Xin-Hua, Hartig, Sean M., Li, Feng, Shen, Haifa, Chen, Yiwen, Han, Leng, Zeng, Qingping, Patterson, John B., Kaipparettu, Benny Abraham, Putluri, Nagireddy, Sicheri, Frank, Rosen, Jeffrey M., Lewis, Michael T., Chen, Xi · 2018 · Journal of Clinical Investigation

Abstract

The unfolded protein response (UPR) is a cellular homeostatic mechanism that is activated in many human cancers and plays pivotal roles in tumor progression and therapy resistance. However, the molecular mechanisms for UPR activation and regulation in cancer cells remain elusive. Here, we show that oncogenic MYC regulates the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) branch of the UPR in breast cancer via multiple mechanisms. We found that MYC directly controls IRE1 transcription by binding to its promoter and enhancer. Furthermore, MYC forms a transcriptional complex with XBP1, a target of IRE1, and enhances its transcriptional activity. Importantly, we demonstrate that XBP1 is a synthetic lethal partner of MYC. Silencing of XBP1 selectively blocked the growth of MYC-hyperactivated cells. Pharmacological inhibition of IRE1 RNase activity with small molecule inhibitor 8866 selectively restrained the MYC-overexpressing tumor growth in vivo in a cohort of preclinical patient-derived xenograft models and genetically engineered mouse models. Strikingly, 8866 substantially enhanced the efficacy of docetaxel chemotherapy, resulting in rapid regression of MYC-overexpressing tumors. Collectively, these data establish the synthetic lethal interaction of the IRE1/XBP1 pathway with MYC hyperactivation and provide a potential therapy for MYC-driven human breast cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci95873

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 239

Metadata

Authors
Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Lv, X., Talukdar, M., Lu, Y., Wang, X., Hu, D. Z., Shi, Q., Xiang, Y., Wang, Y., Liu, X., Bu, W., Jiang, Y., Li, M., Gong, Y., Sun, Z., Ying, H., Yuan, B., Lin, X., Feng, X.-H., Hartig, S. M., Li, F., Shen, H., Chen, Y., Han, L., Zeng, Q., Patterson, J. B., Kaipparettu, B. A., Putluri, N., Sicheri, F., Rosen, J. M., Lewis, M. T., & Chen, X.
Venue
Journal of Clinical Investigation
Published
2018-02-26
Volume
128
Issue
4
Pages
1283-1299
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2788525877
Cited by
239
References
8
FWCI
11.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. https://app.cochat.ai/papers/10.1172/jci95873
The paper
Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Lv, X., Talukdar, M., Lu, Y., Wang, X., Hu, D. Z., Shi, Q., Xiang, Y., Wang, Y., Liu, X., Bu, W., Jiang, Y., Li, M., Gong, Y., Sun, Z., . . . Chen, X. (2018). Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci95873

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.